BioSpace News Archive

Gilead’s regulatory win could open the doors for patients with complicated medication histories and for whom viral suppression regimens have become difficult to create.

With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.

Pfizer is to report initial data from a randomized trial of the second course of therapy of paxlovid in COVID-19 rebound patients by Sept. 2023.

In a letter to shareholders, RegeneRx provided a pipeline update for investors Monday, outlining plans to potentially move forward with a new asset in light of development delays.

Monkeypox is a viral zoonotic disease caused by the monkeypox virus, a member of the orthropox genus in the family poxviridae.

Tessa Therapeutics has tapped former Takeda executive Thomas Willemsen as the man to take its CAR-T portfolio forward.

Across the United States, Clusters of innovation have created self-sustaining ecosystems that are shaping the future of the life sciences industry - and driving economic growth.

United Imaging Healthcare, a leading global medical imaging and radiotherapy equipment company, began trading on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Nykode Therapeutics ASA announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET.

Gilead Sciences, Inc. announced that the European Commission has granted Marketing Authorization for Sunlenca® injection and tablets for the treatment of HIV infection, in combination with other antiretroviral, in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.